Novel Drug Shows Efficacy in Reducing Endometrial Cancer Recurrence and Mortality

A Phase 3 clinical trial, TroFuse-005/ENGOT-en23/GOG-3095, demonstrated that sacituzumab tirumotecan (sac-TMT) significantly lowers the risk of disease recurrence and death in endometrial cancer patients. Published in The Lancet and presented at ESMO, these results suggest a potential new standard of care, particularly for those previously treated with immunotherapy.